01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
19:00 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments follow a Jan. 31 meeting with FDA to discuss an...
23:18 , Feb 5, 2019 |  BC Extra  |  Company News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments Tuesday follow a Jan. 31 meeting with FDA to discuss...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
00:04 , Oct 12, 2018 |  BC Innovations  |  Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Aug. 6 after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan...
18:34 , Aug 6, 2018 |  BC Extra  |  Company News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Monday after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan to...
18:59 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Pain reports Phase I data for AD candidate PTI-125

In October, Pain Therapeutics Inc. (NASDAQ:PTIE) reported data from a Phase I trial of Alzheimer's disease candidate PTI-125 in 24 healthy volunteers showing that single oral doses of 50, 100 and 200 mg were well...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at AACR 2016 Breast cancer amplified sequence 1 (BCAS1)...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Filamin A (FLNA); regulator of calcineurin 1 (RCAN1; DSC1)

Neurology INDICATION: Neurology Rat studies suggest FLNA could help treat periventricular heterotopia (PH) caused by a deficiency in RCAN1 . In rats, shRNA knockdown of RCAN1 in the brain decreased FLNA levels and neuronal migration...